Cost-Effectiveness Analysis of Intensive and Emerging Rehabilitation Therapies in Children With Cerebral Palsy: Real-World Evidence and Microsimulation Modeling
Author(s)
Diana Marcela Nova Diaz, MSc.
PhD student, Public University of Navarra, Pamplona, Spain.
PhD student, Public University of Navarra, Pamplona, Spain.
OBJECTIVES: To evaluate the short- and long-term cost-effectiveness of integrating Intensive and Emerging Rehabilitation Therapies into standard care for children with cerebral palsy (CP), compared to standard care alone, through a hybrid approach combining prospective real-world data analysis and individual-level microsimulation over a lifetime horizon.
METHODS: A prospective cohort of 148 children with CP, stratified by Gross Motor Function Classification System levels, was followed over 12 months. Short-term incremental costs and quality-adjusted life years (QALYs) were estimated using seemingly unrelated regression equations (SURE) based on EQ-5D-Y scores. Costs were assessed from the Spanish public healthcare system perspective. To extrapolate long-term outcomes, an individual-level microsimulation model projected costs and QALYs over a 30-year horizon, applying a 3% annual discount rate.
RESULTS: Compared with standard treatment, Therasuit and intensive physiotherapy demonstrated the most favourable cost-effectiveness profiles. Therasuit generated 0.222 additional QALYs at an incremental cost-effectiveness ratio (ICER) of €18,830/QALY, while intensive physiotherapy generated 0.216 additional QALYs at €31,772/QALY. Other therapies, including occupational therapy and hippotherapy, were dominated by standard care. Lifetime microsimulation reinforced these findings: Therasuit produced 5.49 additional QALYs at an ICER of €12,922/QALY compared to standard care, and intensive physiotherapy produced 4.92 additional QALYs at €25,789/QALY. Homeopathy and the Peto Method were cost-effective under broader willingness-to-pay thresholds but were less efficient.
CONCLUSIONS: Therasuit and intensive physiotherapy represent high-value therapeutic options for children with CP when integrated with standard care. These findings support evidence-based prioritisation of Intensive and Emerging Rehabilitation Therapies in pediatric neurorehabilitation and highlight the importance of combining real-world data with advanced modelling to inform sustainable healthcare resource allocation.
METHODS: A prospective cohort of 148 children with CP, stratified by Gross Motor Function Classification System levels, was followed over 12 months. Short-term incremental costs and quality-adjusted life years (QALYs) were estimated using seemingly unrelated regression equations (SURE) based on EQ-5D-Y scores. Costs were assessed from the Spanish public healthcare system perspective. To extrapolate long-term outcomes, an individual-level microsimulation model projected costs and QALYs over a 30-year horizon, applying a 3% annual discount rate.
RESULTS: Compared with standard treatment, Therasuit and intensive physiotherapy demonstrated the most favourable cost-effectiveness profiles. Therasuit generated 0.222 additional QALYs at an incremental cost-effectiveness ratio (ICER) of €18,830/QALY, while intensive physiotherapy generated 0.216 additional QALYs at €31,772/QALY. Other therapies, including occupational therapy and hippotherapy, were dominated by standard care. Lifetime microsimulation reinforced these findings: Therasuit produced 5.49 additional QALYs at an ICER of €12,922/QALY compared to standard care, and intensive physiotherapy produced 4.92 additional QALYs at €25,789/QALY. Homeopathy and the Peto Method were cost-effective under broader willingness-to-pay thresholds but were less efficient.
CONCLUSIONS: Therasuit and intensive physiotherapy represent high-value therapeutic options for children with CP when integrated with standard care. These findings support evidence-based prioritisation of Intensive and Emerging Rehabilitation Therapies in pediatric neurorehabilitation and highlight the importance of combining real-world data with advanced modelling to inform sustainable healthcare resource allocation.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE206
Topic
Economic Evaluation
Disease
Alternative Medicine, Musculoskeletal Disorders (Arthritis, Bone Disorders, Osteoporosis, Other Musculoskeletal), Neurological Disorders, Pediatrics, Surgery